Abstract: This invention relates to the use of a polypeptide in the production of an immunostimulatory agent, said polypeptide comprising a sequence corresponding to the EDA domain of fibronectin, a fragment of the EDA domain which can bind to TLR4 or a variant of said EDA domain or a fragment which can bind to TLR4 and which has a homology of more than 70% with any form or natural fragment of the EDA domain. The invention also relates to the production methods and applications of said agent.

Abstract: The present invention comprises the use of metalloprotease inhibitors for the treatment of polycystic liver diseases (PLDs). The invention particularly describes the use of Marimastat as the preferred metalloprotease inhibitor for the treatment of PLDs. Treatment with Marimastat is able to inhibit liver cystogenesis by blocking metalloproteolytic hyperactivity of polycystic cholangiocytes.

Abstract: This invention relates to the use of a polypeptide in the production of an immunostimulatory agent, said polypeptide comprising a sequence corresponding to the EDA domain of fibronectin, a fragment of the EDA domain which can bind to TLR4 or a variant of said EDA domain or a fragment which can bind to TLR4 and which has a homology of more than 70% with any form or natural fragment of the EDA domain. The invention also relates to the production methods and applications of said agent.

Abstract: The present invention relates to an immuno-stimulant combination for prophylaxis and treatment of hepatitis C, characterised in that it comprises: a TLR3 agonist, a CD40 agonist and the NS3 protein of the hepatitis C virus. Moreover, the invention relates to the pharmaceutical compositions comprising said immuno-stimulant combination, to the use thereof, and to a kit composed of said pharmaceutical compositions. Finally, the present invention relates to a method for producing an immune response to the hepatitis C virus and to a vaccine against said virus.

Abstract: The invention relates to peptides having the capacity to bind to interleukin-10 (IL-10) and their use in the treatment of clinical conditions or pathological disorders associated to IL-10 expression, particularly to a high IL-10 expression, for example, infectious diseases, tumors, cancers and acute damage conditions.

Abstract: The invention relates to the use of at least one cytokine from the IL-6 family ?gp130, preferably selected from among IL-11, the leukaemia inhibitory factor (LIF), oncostatin M (OSM), cardiotrophin-1, ciliary neurotrophic factor (CNTF), the cardiotrophin-like cytokine (CLC) and combinations thereof or a DNA sequence encoding same, in the preparation of a pharmaceutical composition which is intended for combined administration with at least one IFN-? or a DNA sequence encoding same, for use in the treatment of viral diseases. The invention also relates to a pharmaceutical composition comprising a pharmaceutically-acceptable quantity of at least one cytokin from the IL-6 family ?gp130 or a DNA sequence encoding same and a pharmaceutically-acceptable quantity of at least one IFN-? or a DNA sequence encoding same, a pharmaceutical kit and a method for the treatment of viral diseases with the combined administration of the aforementioned cytokines and IFN-?.

Abstract: The present invention relates to a genic expression adenoviral hybrid vector characterized in that it contains at least the following elements, oriented in the direction 5? to 3?: i. a first chain of adenoviral origin comprising a first inverted terminal repeat (ITR) sequence and a signal sequence for packaging of the adenovirus; ii. a first non-encoding stuffer sequence; iii. a sequence corresponding to a tissue specific promoter; iv. a chain of cDNA derived from an alphavirus, the sequence of which is partly complementary to an alphaviral RNA sequence, comprising at least a sequence encoding for at least one exogenous gene of interest; v. a polyadenylation sequence; and vi.

Abstract: The invention relates to the use of at least one cytokine from the IL-6 family -gp130, preferably selected from among IL-11, the leukaemia inhibitory factor (LIF), oncostatin M (OSM), cardiotrophin-1, ciliary neurotrophic factor (CNTF), the cardiotrophin-like cytokine (CLC) and combinations thereof or a DNA sequence encoding same, in the preparation of a pharmaceutical composition which is intended for combined administration with at least one IFN-? or a DNA sequence encoding same, for use in the treatment of viral diseases. The invention also relates to a pharmaceutical composition comprising a pharmaceutically-acceptable quantity of at least one cytokin from the IL-6 family ?gp130 or a DNA sequence encoding same and a pharmaceutically-acceptable quantity of at least one IFN-? or a DNA sequence encoding same, a pharmaceutical kit and a method for the treatment of viral diseases with the combined administration of the aforementioned cytokines and IFN-?.

Abstract: The invention relates to peptides of general formula (I), wherein X is absent or X is present and is X14 or X14-X15, wherein X14 and X15, independently from one another, represent an amino acid; their functional variants and fragments, and their pharmaceutically acceptable salts, having the capacity to bind to scurfin and inhibit its biological activity, therefore they regulate or block the activity of regulatory T (Treg) lymphocytes. They are applicable in the treatment of infectious and neoplastic diseases.

Abstract: The described peptides possess the capacity to bind to Transforming Growth Factor TGF-?1 (TGF-?1), and are potential inhibitors of the biological activity of TGF-?1 through direct binding to this cytokine. These peptides can be used in the treatment of diseases or pathological alterations based on excessive or deregulated TGF-?1 expression, e.g., liver fibrosis, pulmonary fibrosis, corneal fibrosis and haze.

Abstract: The invention relates to peptides having the capacity to bind to interleukin-10 (IL-10) and their use in the treatment of clinical conditions or pathological disorders associated to IL-10 expression, particularly to a high IL-10 expression, for example, infectious diseases, tumors, cancers and acute damage conditions.

Abstract: Use of cardiotrophin in liver diseases. The invention describes the increased expression of cardiotrophin (CT-1) during the process of hepatic regeneration coinciding with maximum proliferation of hepatocytes and the role of CT-1 as a stimulator of hepatic regeneration. Furthermore, it describes the hepatoprotective role of CT-1 in various models of acute liver damage. The importance of using CT-1 in the manufacture of compositions for use in the treatment of hepatopathies is demonstrated. The invention describes such use in various forms and methods, including the recombinant protein and the use of the gene sequences that code for CT-1.

Abstract: The invention relates to a viral vector comprising a mutated replicon of the Semliki Forest virus (SFV) in the nucleotide sequence encoding subunit nsp2 of the SFV replicase. Said viral vector can be used to generate stable cell lines which can constitutively express heterologous products of interest.

Abstract: The present invention relates to an immuno-stimulant combination for prophylaxis and treatment of hepatitis C, characterised in that it comprises: a TLR3 agonist, a CD40 agonist and the NS3 protein of the hepatitis C virus. Moreover, the invention relates to the pharmaceutical compositions comprising said immuno-stimulant combination, to the use thereof, and to a kit composed of said pharmaceutical compositions. Finally, the present invention relates to a method for producing an immune response to the hepatitis C virus and to a vaccine against said virus.

Abstract: The described peptides possess the capacity to bind to Transforming Growth Factor TGF-?1 (TGF-?1), and are potential inhibitors of the biological activity of TGF-?1 through direct binding to this cytokine. These peptides can be used in the treatment of diseases or pathological alterations based on excessive or deregulated TGF-?1 expression.

Abstract: The present invention relates to the use of a peptide inhibiting TGF-?1 selected from: peptide p144 whose sequence corresponds to SEQ ID NO: 1, peptide p17 whose sequence corresponds to SEQ ID NO: 2, a peptide which has at least 90% homology therewith, or fragments of the above, in the preparation of an immune response modulating agent.

Abstract: This invention relates to the use of a polypeptide in the production of an immunostimulatory agent, said polypeptide comprising a sequence corresponding to the EDA domain of fibronectin, a fragment of the EDA domain which can bind to TLR4 or a variant of said EDA domain or a fragment which can bind to TLR4 and which has a homology of more than 70% with any form or natural fragment of the EDA domain. The invention also relates to the production methods and applications of said agent.

Abstract: A Method for the treatment of skin fibrosis with a peptide that inhibits TGF-?, and suitable compositions for its administration. The method includes in particular, the use of peptide P144, a compound that is a known inhibitor of TGF-?, for the treatment of skin fibrosis by topical application. The method is shown effective in an animal model of bleomycin-induced skin sclerosis, to a reduction both of the skin fibrosis and of the content of soluble collagen, without any signs of systemic toxicity being detected. This shows that P144 is effective for topical application in mammals for treating fibrotic skin diseases and pathological scarring of the skin. For the administration of this peptide, stable compositions are also supplied, with pleasant appearance without being greasy, with good spreading characteristics and with a viscosity that permits it to be processed easily in industrial plant, and which are suitable for administering the peptide to humans.

Abstract: By means of a proteomic approach, the markers of hepatocellular carcinoma (HCC) in the liver of a knockout mouse (MAT1A?/?) have been identified for the MAT1A gene (deficient in the synthesis of S-adenosylmethionine). 27 proteins have been detected the expression thereof is altered in, at least, 50% of the analysed tumours. Amongst them, 13 proteins have been validated in biopsies of patients with HCC of different etiology, and 7 of them have been validated in biopsies of patients with liver cirrhosis, a stage prior to the development of HCC, which makes it possible to differentiate between prior stages of the disease and even between different etiologies (viral and alcoholic). Having a panel of markers available may contribute to more accurately defining the alterations associated with the development of HCC and thus facilitate prognosis and diagnosis of this disease.

Abstract: The invention relates to the use of at least one cytokine from the IL-6 family ?gp130, preferably selected from among IL-11, the leukaemia inhibitory factor (LIF), oncostatin M (OSM), cardiotrophin-1, ciliary neurotrophic factor (CNTF), the cardiotrophin-like cytokine (CLC) and combinations thereof or a DNA sequence encoding same, in the preparation of a pharmaceutical composition which is intended for combined administration with at least one IFN-? or a DNA sequence encoding same, for use in the treatment of viral diseases. The invention also relates to a pharmaceutical composition comprising a pharmaceutically-acceptable quantity of at least one cytokin from the IL-6 family ?gp130 or a DNA sequence encoding same and a pharmaceutically-acceptable quantity of at least one IFN-? or a DNA sequence encoding same, a pharmaceutical kit and a method for the treatment of viral diseases with the combined administration of the aforementioned cytokines and IFN-?.